Compare Levi Strauss & Co. (LEVI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs TransMedics Group Inc — how do they compare? Levi Strauss & Co. trades at $18.65 (market cap $7.31B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Levi Strauss & Co. is far larger — about 2.7× TransMedics Group Inc's market cap, and Levi Strauss & Co. pays a 3.36% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and TransMedics Group Inc for 24 Days on average.
| LEVI | TMDX | |
|---|---|---|
Market Cap | $7.31B | $2.74B |
Volume | 13,683,095 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $150.42 |
52-Week Low | $17.92 | $61.99 |
Typical Hold Time | 70 Days | 24 Days |
Enterprise Value | $8.86B | $3.13B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $18.71, down 4.13% today, with a bearish technical outlook despite strong fundamentals. The company has beaten earnings estimates for four consecutive quarters, maintains a healthy gross margin of 62.81%, and shows improving cash flow trends. Analyst consensus remains strongly bullish with a $29.00 price target, representing 55% upside potential from current levels.
The stock presents a compelling value opportunity with a P/E of 12.5x and strong brand momentum, though technical weakness and recent cybersecurity incidents pose near-term risks. Wall Street's overwhelming buy rating (79%) suggests confidence in Levi's direct-to-consumer strategy and international expansion driving future growth.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
